D-0033-2018 Class III Terminated

Recalled by AbbVie Inc. — North Chicago, IL

FDA drug recall D-0033-2018 was initiated by AbbVie Inc. on Sep 8, 2017 and is designated Class III. Reason for recall: Temperature Abuse: Prolonged exposure to temperatures outside of labeled storage conditions. The recall status is terminated (terminated Apr 23, 2018). Affected quantity: 520 pumps.

Recall details

Product Type
Drugs
Report Date
Nov 1, 2017
Initiation Date
Sep 8, 2017
Termination Date
Apr 23, 2018
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
520 pumps

Product description

AndroGel (testosterone gel) 1.62%, 88 gm metered-dose pump, 20.25 mg of testosterone per pump actuation, 60 metered pump actuations, Rx Only, Marketed by: AbbVie Inc., North Chicago, IL 60064 USA. NDC: 0051-8462-33

Reason for recall

Temperature Abuse: Prolonged exposure to temperatures outside of labeled storage conditions.

Distribution pattern

AZ

Code information

Lot: 91122, EXP. 01/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0033-2018
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0033-2018. Report a data issue: hello@regdatalab.com.